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Abstract 
The sarcoplasmic reticulum is an internal membrane system that controls the Ca2+ 
concentration inside muscle cells, and hence the contractile state of both skeleal and 
cardiac muscle. A key protein that that regulates the Ca2+ concentration in this 
membrane is known as the calcium release channel (CRC). The effects on Ca2+ 
dependent activation is of major importance in the study of CRC since other channel 
modifiers cannot effect the channel in the absence of Ca2+, or they require Ca2+ for 
maximum results. In this study of the high-affinity Ca2+ binding site, expected 
increases in total binding and shifts in the sensitivity of the channel to Ca2+ were 
observed when the pH increased or the solution redox status became more oxidative. 
Ranolazine, a drug used for treating Angina Pectoris (chest pain), desensitized the 
cardiac CRC activation but had no effect on the skeletal CRC. This selective 
desensitization may be the cause of Ranolazine’s beneficial therapeutic effects. Both 
Ranolazine, and homocystein thiolactone (HCTL), a naturally occurring derivative of 
homocysteine, alters Ca2+ dependent activation by calcium without changing the 
number of channels found in the open state. Surprisingly the effect of HCTL was 
observed only in a reduced redox potential which leads to speculation that the 
formation of an alpha-carbon radical by HCTL on the cardiac CRC only occurs if 
select thiols are in a reduced state. 
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1.1 The contraction of a muscle cell
Vertebrate muscle provides mechanical force upon stimulation and can be separated 
into three types; skeletal, cardiac and smooth. In muscle cells, filaments called 
myofibrils are surrounded by the sarcoplasmic reticulum (SR
that is periodically penetrated by the transverse tubular system (T
of approximately 1.2µm in skeletal muscle fibers and 2.5µm in cardiac ventricles. The 
initiation of contraction is provided by an electrical e
potential that travels along the surface membrane of the muscle cell and down the T
tubules allowing the action potential to travel 
fiber rapidly. The time that it takes skeletal muscle to 
where as cardiac muscle is slightly slower taking 20
 
Figure 1: The sarcoplasmic reticulum and transverse tubule system of 
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T-tubules are separated from the terminal cisternae3 of the SR by approximately 10nm 
and the interaction between them is referred to as excitation-contraction coupling 
(ECC). In this process three things must happen; the detection of the propagation of n 
action potential along the T-tubules, the transmission of the information by the 
dihydrophridine receptor (DHPR) to the Calcium Release Channel (CRC), and fin lly 
the release of calcium from the SR. Figure 2 shows a schematic of the flow of calcium 
out of the SR through the CRC where it binds to troponin at micromolar 
concentrations, initiating contraction. After calcium is released from the SR, the Ca2+-
Mg2+-ATPase (Ca2+ pump) a 110kDa protein, pumps the calcium back into the lumen 
of the SR causing the muscle to relax.  
 
 
Figure 2: Excitation-contraction model4 
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One of the major differences between cardiac and skeletal muscle is that ECC in 
cardiac muscle requires a small amount of Ca2+ to cross the T-tubule, whereas in 
skeletal muscle ECC is independent of the extracellular calcium5. The activation of the 
CRC by calcium in cardiac muscle proceeds by a mechanism known as calcium 
induced calcium release.6  
 
1.2 Impact of abnormal Intracellular Ca2+ cycling 
Problems with intracellular Ca2+ cycling have been associated with heart failure, 
ischemic heart disease, and in several genetic forms of arrhythmias7. Heart failure is 
characterized by abnormal intracellular Ca2+ cycling that leads to progressive 
deterioration of cardiac function. Associated with heart failure is the inability of the 
SR to build up an adequate Ca2+ load required for generating contraction, due to an 
increased Ca2+ leak associated with the RyR2 channel. In cardiac muscle there are 
additional proteins not found in skeletal muscle. Since Ca2+ enters the cell through the 
DHPR to initiate cardiac muscle contraction there must be a mechanism of purging 
Ca2+ from the cell. The Na+/ Ca2+ exchange protein (NCX) moves three Na+ ions into 
the cell and one Ca2+ ion out of the cell. This is the primary mechanism for maintain 
low intracellular Ca2+ concentrations in spite of the fact that Ca2+ enters the cell on 
each beat of the heart. An abnormal Ca2+ leak from the SR during the relaxation phase 
of the heart, when the cytosolic Ca2+ concentrations should be low, have been shown 
to cause arrhythmias known as delayed afterdepolarizations (DADs)8. When 
intracellular Ca2+ levels rise the NCX assists in removing the Ca2+ from the cell, which 
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results in the influx of sodium and can lead to a depolarization of the extracellul r 
membrane. This unsynchronized action potential can generate arrhythmias. CRCs that 
have a diastolic Ca2+ leak have consequently become a therapeutic target. 
 
1.3 Calcium Release Channel 
The calcium release channel is a cation selective trans membrane protein that is 
thought to be a homotetramer with each of its subunits having a molecular weight of 
about 565kDa. These subunits are arranged in a quatrefoil shape, 22 to 27nm on each 
side with a 2nm hole in the center9. The plant alkaloid ryanodine binds to this protein 
with high affinity and high selectivity when the channel is in its open state10. B cause 
of this, the channel is commonly referred to as the ryanodine receptor (RyR). The RyR 
has three isoforms known as RyR1, RyR2 and RyR3. All three isoforms appear in 
brain tissue, however RyR1 is found predominately in skeletal muscle, while RyR2 is 
found primarily in cardiac muscle.  
 
 
 
Figure 3: 3D reconstruction of the calcium release channel protein  
(commonly known as the ryanodine receptor).11 
 
 
 
5 
 
1.4 Modification of Ca2+ Release 
Ca2+ has a biphasic role in the regulation of Ca2+ release. Low micromolar 
concentrations stimulate the channel while high concentrations (>1mM) inhibit the 
channel. This bell shaped Ca2+ dependence curve has been hypothesized to result from 
two different binding sites, a high affinity site that opens the channel and a low 
affinity site that inhibits release.12 While a rise in the Ca2+ concentration in the cytosol 
is the principal factor stimulating the CRC13 in cardiac muscle, in skeletal muscle, 
where ECC is independent of extracellular Ca2+ another mechanism of information 
transfer must be present. It is generally believed that there is some type of 
conformational coupling between the DHPR and the Ryanodine Receptor in skeletal 
muscle but the precise mechanism is unknown.  
 
There is direct evidence, however, for the existence, location and function of 
hyperreactive thiols which have been reported in both skeletal14 and cardiac muscle15. 
Figure 4 shows a proposed model of the Ca2+ release channel that is regulated by 
several classes of sulfhydryl  groups existing in close proximity and able to form 
mixed disulfides. Oxidation of these hyperreactive sulfhydryl groups to a disulfi e 
linkage which opens the channel (S1- 2), is then followed by thiol-disulfide exchange 
(S2-S3) that closes the channel, and finally, reduction of the disulfide bond by the 
cellular oxidoreductive (redox) environment which resets the redox status. In support 
of this model, it has been shown that the CRC has a well defined reduction potential 
that is sensitive to the cellular environment.16 Channel activators lower the redox 
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potential, making the value more negative, which favors the oxidation of thiols and the 
opening of the channel, while channel inhibitors increase the redox potential to more 
positive values, which favors the reduction of disulfides and the closure f th channel. 
During oxidative stress or ischemia, these hyperreactive thiols could oxidize and alter 
the Ca2+ sensitivity of the CRC allowing small changes in the calcium concentrations 
to contribute to significant activation and release of Ca2+.
 
Figure 4: Model of the Ca2+ release protein gated by SH oxidation  
and reduction of three endogenous SH groups.17 
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Glutathione (GSH) is part of an antioxidant system and plays an important part in 
maintaining the cellular redox status. It shares the job of scavenging peroxide, singlet 
oxygen and other free radicals, with antioxidant vitamins and antioxidant enzymes, 
and is the most abundant nonprotein thiol source in the muscle cell18. The eye lens has 
the highest GSH concentrations at ~10mM, whereas muscle has about 1-2mM19. 
During excessive production of reactive oxygen species (ROS) GSH donates a pair of 
electrons to a hydroperoxide, resulting in 2 GSH being oxidized to 1 glutathione 
disulfide (GSSG). The GSSG can then be reduced back to GSH by NADPH, which is 
catalyzed by glutathione reductase (GR). When production of the ROS overwhelms 
the recycling capacity of the GR, GSSG levels rise, resulting in a decrease of the 
GSH/GSSG ratio and a more oxidized environment. While GSSG by itself is a 
activator of the channel, and GSH is a known inhibitor it has been reported that ratio 
of GSH/GSSG rather than the total GSH or total GSSG concentrations determine the 
response of the RyR20. The typical mammalian cell ratio of [GSH]/[GSSG] in the 
cytosol is ≥30:1 resulting in a reduction potential of approximately -230mV21.  Trans-
membrane redox potential differences are on the order of 50mV with the lumen of the 
SR being more oxidized than the cytosol30. 
  
1.5 Regulation of the calcium dependence of the CRC by [H+] 
During myocardial ischemia, when the flow of oxygenated blood to the myocardium is 
diminished, the cellular pH can fall to as low as pH5.822. This condition, called 
acidosis, has been shown to reduce the open probability of the isolated CRC 
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incorporated into lipid bilayers23 which produces an increase in SR Ca2+ content, and 
is also likely to decrease cytoplasmic Ca2+ buffering since Ca2+ and H+ ions share 
common binding sites within both the skeletal and cardiac cell24. Therefore the pH 
dependent inhibition of the CRC likely influences the physiological mechanism of 
calcium induced calcium release. 
 
1.6 Studied Compound - Ranolazine  
The drug Ranolazine was approved for the treatment of Angina Pectoris (chest pain) 
and ischemic heart disease in 1996 by the FDA. While Ranolazine at micromolar 
concentrations is beneficial, it has been shown that it interacts with various ion 
channels and metabolic pathways leaving the exact mechanism of the useful effects in 
question. It is proposed that the beneficial effect of Ranolazine is due to a decrease in 
a spontaneous Ca2+ leak across the SR membrane, not the previously proposed shifting 
of myocardial energy metabolism from fatty acid to glucose oxidation25.  
 
Figure 5: (RS)-N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)-
propyl]piperazin-1-yl]acetamide26 
 
1.7 Studied Compound -  Homocysteine Thiolactone 
It has been established that increases in homocysteine levels is a risk factor for 
cardiovascular disease and stroke in humans27. The thioester Homocysteine 
Thiolactone (HCTL) is one of many metabolites of Homocysteine. Preliminary results 
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indicate it can activate the CRC at nanomolar concentrations. A possible mechanism 
by which the HCTL may react with the CRC is through lysine residues on the RyR 
which may form alpha-amino carbon-centered radicals28  shown in Figure 6.  
 
 
Figure 6: HCTL, an activated carbonyl, conjugates readily to  
lysine residues of proteins. 
 
It is widely accepted that a majority of protein backbone cleavage and related damage 
occurs via alpha-carbon radicals of amino acid residues. It has also been shown that 
cysteinyl residues and glutathione may aid the formation of alpha-carbon radicals on 
protein residues29. Other possibilities include the α-amino group of HCTL reacting 
with aldehydes on the protein. It has been shown that the rate constant of HCTL 
reacting with streptomycin occurs with a half life of 10 minutes which is 400 times 
faster than the rate at which it reacts with lysine30. Other possibilities of HCTL 
interaction are the oxidation of critical thiols or the homocysteinylation of the RyR 
protein.  
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Chapter 2: Materials and Methods 
 
2.1 Materials 
Tritium labeled ryanodine ([3H]-ryanodine) was purchased from PerkinElmer Life & 
Analytical Sciences, Boston Massachusetts and stored in the freezer at -18˚C. 
Unlabeled ryanodine was purchased from AgriSystems International, Wind Gap, 
Pennsylvania. A stock solution was prepared at 10mM in 50% Methanol/deionized 
distilled nanopure water. White New Zealand rabbits were purchased from Western 
Oregon Rabbit Company, Philomath, Oregon. Ketamine HCl and Acepromazine 
Maleate was purchased from the veterinary pharmacy at Oregon Health and Scie ce 
University, Portland, Oregon. Sheep hearts were a gift from Dr. Kent Thornburg, 
Heart Research Center, Oregon Health and Science University, Portland, Oregon. 
Ethylene glycol tetraacetic acid (EGTA) was purchased from Research Organics, 
Cleveland, Ohio, and prepared in deionized distilled nanopure water and stored at 
room temperature. CytoScint scintillation fluid was purchased from MP Biomedicals, 
Costa Mesa, California. Homocysteine Thiolactone (HCTL) was a gift from Dr. 
Robert M. Strongin, Department of Chemistry, Portland State University, Portland, 
Oregon. HTLC stock solution was freshly prepared at less than 30µM in buffer 
containing 250mM KCl, 15mM NaCl, and 20mM Piperazine-1,4-bis(2-ethanesulfonic 
Acid (PIPES) set to pH 7.1 with KOH unless otherwise noted. Ranolazine was a gift 
from Dr. Guy Salama, Department of Cell Biology and Physiology, University of 
Pittsburgh, Pittsburgh, Pennsylvania. A Ranolazine stock solution was freshly 
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prepared with 95% ethanol, which was purchased along with all other chemicals not 
listed above from Sigma Aldrich, St. Louis, Missouri. Glutathione in both its oxidized 
and reduced form was prepared on ice in ice cold deionized distilled nanopure water 
containing 10µM EGTA at a concentration of 0.5M. Once the pH was adjusted to pH 
7.0, aliquots were frozen in liquid N2.  
 
2.2 Skeletal SR Preparation 
Skeletal muscle SR vesicles were isolated from the fast twitch muscle of a 2-3 kg 
White New Zealand male rabbit based on the method of MacLennan.31 Euthanizing 
solution consisting of 58.8mg/ml Ketamine, 5.88mg/ml Xylazine, and 1.18mg/ml 
Acepromazine Maleate was subcutaneously injected at a dose of 0.5ml/kg. Rabbit’s 
jugular vein was cut and muscle was removed from the back and hind legs. After 
removing the fat and connective tissue, muscles was minced and placed in a buffer 
containing 120mM NaCl, 10mM Imidazole, 100µM Dithiothreitol (DTT), 100µM 
EGTA, 0.1mM phenylmethanesulfonyl-fluoride (PMSF), 0.2µg/ml leupeptin, and 1 tablet 
per 500ml of EDTA free SigmaFAST protease Inhibitor Cocktail tablets (Skeletal 
Buffer A). Muscle was then blended for three cycles at a low speed for 15 seconds, 
high speed for 60 seconds, followed by a 30 second rest period. The resulting solution 
was centrifuged in a large Fiberlite rotor at 1600 x g for 10 minutes at 4˚C to remove 
cell debris. The supernatant was then filtered through four layers of cheeseloth and 
adjusted to pH7.4 with dry Imidazole. The filtrate was then spun in a Type 19 rotor at 
10,000 x g  for 15 minutes at 4˚C. The brown pellet composed of mitochondria was 
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discarded and the supernatant was then filtered through four layers of cheesecloth. The 
filtrate was then spun at 50,000 x g for 70 minutes at 4˚C. The resultant pellet which 
consists of SR and myosin was then homogenized in 120mM NaCl, 10mM Imidazole, 
100µM DTT, 50µM EGTA, 0.2µg/ml leupeptin, and 1 tablet per 500ml of EDTA free 
SigmaFAST protease Inhibitor Cocktail tablets (Skeletal Buffer B). The solution was 
then spun at 7,500 x g in a Ti-60 rotor for 10 minutes at 4˚C. The resulting myosin 
pellet was discarded and the spin was repeated. The final supernatant, after removing 
the second myosin pellet was then spun at 123,000 x g for 30 minutes at 4˚C which 
resulted in a SR pellet. That pellet was homogenized in a buffer containing 100mM 
KCl, 20mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.0 
(KOH).  Once the protein concentration was determined, and diluted, if needed, to 
approximately 20mg/ml,  the crude skeletal SR aliquots were stored in liquid N2 ntil 
needed. 
 
2.3 Cardiac SR Preparation 
Cardiac SR vesicles were isolated from Sheep hearts obtained from OHSU based on 
the method of Meissner and Henderson.32 Once the heart was removed from the sheep, 
it was immersed in ice cold buffer containing 300mM Sucrose, 10mM PIPES, 0.5mM 
PMSF, 1µg/ml Leupeptin at pH 7.4 with KOH (Cardiac Buffer A). The atria and other
connective and fatty tissue were removed and the remaining ventricles were minced 
into small pieces to be blended at high speed in a waring blender for 20 seconds. After 
a 30 second rest period the solution was blended again on high for 20 seconds. The 
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resultant solution was centrifuged at 9,000 x g in the large fiberlite rotor at 4˚C. The 
supernatant was then filtered through two layers of cheesecloth and spun at 44,000 x g 
for 75 minutes in a type 19 rotor at 4˚C. The resultant pellet was homogenized in 
Cardiac Buffer A and spun at 25,000 x g for 30 minutes at 4˚C. The resulting SR pellet 
was homogenized in a buffer containing 100 mM Sucrose, 5 mM HEPES at pH 7.2 
(Tris-base). Once protein concentration was determined, and diluted if needed to 
approximately 20mg/ml,  the crude cardiac SR aliquots were stored in liquid N2. 
 
2.4 Protein Determination 
Protein concentrations of the SR were determined by the method of Kalckar33. The 
absorbance peak at 280nm is mainly due to the presence of tyrosine and tryptophan 
and the peak at 230nm is mainly due to the peptide bond of the protein backbone. 
Using this information, absorption was measured on an Agilent 8453 UV-Visible 
photodiode array spectrophotometer at 230nm and 280nm . Data was also collected at 
260nm in order to correct for nucleic acids using the following equations. 
 
[SR]mg/ml = 1.45 x Abs280 – 0.74 x Abs260                        (Equation 1) 
 
[SR]mg/ml = 0.185 x Abs230 – 0.748 x Abs260                              (Equation 2) 
 
The process was repeated twice, and the average protein concentration was calcul ted. 
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2.5 Equilibrium Ryanodine Binding Assay 
The molecule ryanodine binds with nanomolar affinity to a single class of proteins 
near the junctional region of the SR34 under certain conditions. With a few exceptions, 
such as silver, CRC activators stimulate ryanodine binding, whereas compounds that 
inhibit the CRC, inhibit binding. Tritium labeled ryanodine ([3H]-ryanodine) binding 
assays were carried out at a [3H]ryanodine concentration of 1nM, and 14nM unlabeled 
ryanodine for skeletal SR, and a [3H]ryanodine concentration of 2nM, and 13nM 
unlabeled ryanodine for cardiac SR. SR vesicles (0.5mg/ml) were incubated in a 
buffer containing 250mM KCl, 15mM NaCl, and 20mM Piperazine-1,4-bis(2-
ethanesulfonic Acid (PIPES), pH 6.8, 7.1 or 7.4 as dictated by each experiment, at 37˚ 
Celsius for 3 hours in order for binding to reach equilibrium. Samples were then 
quenched by rapid filtration through Whatman glass fiber filters using a Brandel cell 
harvester. Filters were washed twice with approximately 4ml of buffer containing 
250mM KCl, 15mM NaCl, 20mM tris-(hydroxymethyl)- aminomethane (TRIS), and 
100µM CaCl2 at pH 7.1 (HCl). These filters were then dried in an oven at 50˚C for 
two hours then incubated with agitation in 3ml of CytoScint scintillation fluid for one 
hour. Radioactivity was counted by a Beckman LS 6000 scintillation counter with an 
efficiency of approximately 55%. Nonspecific binding was measured in the presnce 
of 200nM unlabeled ryanodine, and 4mM ethylene glycol tetra acetic acid (EGTA). 
Total specific activity was determined by adding an extra aliquot of experimental 
[3H]-ryanodine buffer solution to scintillation fluid and counting the sample. 
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2.6 Initial Rate Ryanodine Binding Assay 
Binding kinetics were determined in a similar manner to equilibrium Ryanodine 
binding experiments described above with small modifications. When working with 
skeletal SR vesicles the addition of 1nM  [3H]-ryanodine occurred over four time 
points, three minutes apart before being quenched with rapid filtration. When working 
with cardiac SR vesicles the addition of 4nM [3H]-ryanodine occurred over four time 
points, five minutes apart before being quenched with rapid filtration.  
 
2.7 Hill Analysis 
Calcium dependent ryanodine binding measurements were fit to the Hill equation.  
 
n
d
n
xk
x
BB
][
][
max +
=
                                                  
(Equation 3) 
 
Where Bmax is the maximum binding, [x] is the free Ca
2+ concentration determined 
with the computer program “Bound and Determined”, kd is the dissociation constant of 
the binding site and n is the Hill coefficient. The graphing software SigmaPlot was 
used to determine the best fit parameters for the half maximal binding concentration 
(EC50) which was calculated by equation 4. 
 






= ndkEC
1
50                                                 (Equation 4) 
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2.8 Redox Potential 
To study the effects of channel modulators in more reduced or oxidized environments 
it is possible to mimic the cellular redox status by using various concentratio s of 
GSH and GSSG determined by the following equation. 
 
                                                                                                                   (Equation 5) 
 
Where Esolution is the redox potential of the solution, E˚ is the standard potential of 
glutathione (-0.24V), pHactual is the pH of the buffer, R is the gas constant (8.31 deg
-1 
mol-1), T is the absolute temperature (K), n is the number of electrons transferred (n 
=2 for glutathione) and F is the Faraday constant (96406 J/V).  
 
2.9 Redox titrations 
SR vesicles were incubated at various solution redox potentials and channel modifiers 
for 1 hr at 37˚C before measurement of the initial rate of ryanodine binding assay was 
started with the addition [3H]ryanodine. Values for the maximum initial rate of 
Ryanodine binding, Bmax, were obtained from each individual redox titration at its 
most oxidized point, and the minimum initial rate of Ryanodine binding, Bmin was 
obtained from its most reduced point. With these values  Equation 6 was used to plot 
Esolution as a function of the initial rate of Ryanodine binding, Bʹ, resulting in a curve 
in which the x intercept determines the redox potential of the RyR, ERyR.
 	 2.3 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Chapter 3: Results 
 
3.1 Ca2+ dependence of Cardiac and Skeletal SR at various pH and redox potentials. 
The Ryanodine Receptors found in cardiac muscle have different sensitivities to 
activators and inhibitors than those that are found in skeletal muscle. This variation in 
response is unlikely due to the difference in species as it has been reported that 
preparations from diverse species such as mouse, rabbit, and sheep exhibit similar 
trends, especially with respect to Ca2+ sensitivity35.  It has also been shown previously 
that Ryanodine Binding is affected by pH36,37,38 with optimal binding between pH 7.2 
and pH 7.8 39. Figure 7 shows that ryanodine binding to rabbit skeletal muscle SR 
reaches a maximum between 30-100µM free Ca2+ at pH 7.4 and between 3-10 µM 
free Ca2+ at pH 6.8 after a gradual increase in binding. Sheep cardiac muscle SR has a 
sharper response to Ca2+ than skeletal muscle SR showing a higher degree of 
cooperativity and reaches maximum binding between 300-700nM free Ca2+ at pH 7.4 
and a maximum binding between 700nm-3 µM free Ca2+ at pH 6.8. There is also 
significantly higher binding of ryanodine to skeletal muscle SR at pH 7.4 than to 
cardiac muscle SR. At pH 6.8 there is little difference observed in maximal ryanodine 
binding to skeletal vs. cardiac muscle SR. Although there are differences in the Ca2+ 
dependence of ryanodine binding at pH 7.4 vs. pH 6.8, large changes in maximal 
binding between skeletal and cardiac SR are only observed at pH 7.4. 
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Figure 7: Ca2+ dependent ryanodine binding as a function of pH in skeletal and 
cardiac muscle SR. Skeletal muscle SR at pH 7.4 (●), pH 6.8 (■). Cardiac 
muscle SR at pH 7.4 (♦), pH 6.8 (▼). 
 
The oxidation state of the cysteine residues on the cytoplasmic domain of the RyR 
have been shown to be important in determining the calcium sensitivity of the RyR40. 
Shown in Figures 8 and 9, and summarized in Table 1, are the effects of two different 
redox potentials on Ca2+ dependent ryanodine binding to skeletal muscle SR. 
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Effects of Redox Solution Potential on Ca2+ 
dependence of ryanodine binding
in Skeletal muscle at pH 7.4
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Figure 8: Shift in Ca2+ 
dependent ryanodine 
binding due to solution 
redox potential at pH 
7.4. Control Skeletal 
muscle SR at pH 7.4 (●);  
-90mV solution redox 
potential (■); -200mV 
solution redox potential 
(▼). 
 
Effects of Redox Solution Potential on Ca2+ 
dependence of ryanodine binding
in Skeletal muscle at pH 6.8
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Figure 9: Shift in Ca2+ 
dependent ryanodine 
binding due to solution 
redox potential at pH 
6.8. Control Skeletal SR 
at pH 6.8 (●); -90mV 
solution redox potential 
(■); -200mV solution 
redox potential (▼). 
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 Skeletal 
Muscle SR 
Control 
Skeletal 
Muscle SR 
-200mV 
Skeletal 
Muscle SR 
-90mV 
Cardiac 
Muscle SR 
Control 
kd at pH 6.8 
(µM) 
0.8±0.1 2.5±0.3 0.5±0.1 0.9±0.1 
kd at pH 7.4 
(µM) 
0.4±0.1 0.4±0.1 0.3±0.1 0.1±0.1 
Maximal 
ryanodine binding 
at pH 6.8 
(pmol/mg) 
1.0 0.8 1.2 0.9 
Maximal 
ryanodine binding 
at pH 7.4 
(pmol/mg) 
2.3 1.5 2.7 1.1 
 
Table 1: Shift in kd Ca
2+ and maximum binding due to pH and solution redox potential. 
 
As summarized in Table 1 at both pH 6.8 and pH 7.4, a more oxidizing solution redox 
potential increases maximal ryanodine binding. At pH 7.4 sensitivity of the RyR1 to 
activation by lower Ca2+ concentrations is increased.  
 
3.2 Shift in Redox Potential of the RyR as a function of pH 
It has previously been shown that the ryanodine receptor acts as a redox sensor35. 
Channel activators shift the redox potential of the receptor to a more negative or 
reduced value. This results in the oxidation of critical thiols to disulfides. In contrast 
channel inhibitors shift the redox potential of the receptor to a more positive, or more 
oxidized potential resulting in the reduction of disulfide bonds and a decrease in the 
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rate of ryanodine binding. Figure 10 & Figure 11 show redox titrations at three 
different pH values and demonstrates that at lower pH thiols require stronger oxidizing 
conditions to activate the channel. This shift in value is expected as the –S- form is 
more easily oxidized than the –SH form. The ERyR values for each titration are 
summarized in Table 2. 
 
 pH 6.8 pH 7.1 pH 7.4 
Skeletal Muscle SR -88mV -133mV -155mV 
Cardiac Muscle SR -141mV -217mV -236mV 
 
Table 2: ERyR values for skeletal muscle SR and cardiac muscle SR redox  titration as 
a function of pH. 
 
Redox titrations as a function of pH
(Skeletal Muscle)
Redox potential (mV)
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Figure 10: Shift of redox 
potential titration as a function 
of pH in skeletal muscle SR. 
pH 6.8 (●),   
pH 7.1 (▼),  pH 7.4 (■). All 
experiments are carried out 
with 50µM free Ca2+. 
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Redox titrations as a function of pH
(Cardiac Muscle)
Redox Potential (mV)
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Figure 11: Shift of redox 
potential titration as a function 
of pH in cardiac muscle SR. 
pH 6.8 (●),  pH 7.1 (▼),  pH 
7.4 (■). All experiments are 
carried out with 50µM free 
Ca2+. 
 
 
 
 
3.4 Change in Ca2+ dependent ryanodine binding due to the drug Ranolazine 
Conditions that are associated with increased channel open probabilities in single 
channel artificial lipid bilayer experiments are usually associated with increases in 3H-
Ryanodine binding measurements. Ranolazine is one of the exceptions. No effect on 
Ryanodine binding was seen in cardiac or skeletal muscle as a function of increasing 
concentration of Ranolazine, however at the single channel level an inhibition with a 
kd of 10 ± 3 µM in cardiac SR vesicles (Yanping Ye ~ unpublished data) was shown. 
As the therapeutic effects of Ranolazine are due to decreasing intracellular Ca2+ load 
the effects of 30µM Ranolazine in cardiac SR  were studied and a shift in the Ca2+ 
dependence of Ryanodine binding was observed at both pH7.1, where the kd shifted 
from 0.49µM ± 0.02 to 0.66µM ± 0.03 and at pH 7.4 where the kd shifted from 
0.03µM ± 0.01 to 0.04µM ± 0.01 as shown in Figure 12.  
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Figure 12: Ca2+ dependent ryanodine binding in cardiac muscle SR with and 
without 30µM Ranolazine. Control at pH 7.1 (black sphere ●); +30µM Ranolazine 
at pH 7.1 (black triangle ▲); control at pH 7.4 (red sphere ●); +30µM Ranolazine 
at pH 7.4 (red triangle▲). 
 
 
3.5 Ca2+ dependence of Homocysteine Thiolactone 
Homocysteine thiolactone like ranolazine does not affect maximal 3H-Ryanodine 
binding measurements over the range of concentrations that it is soluble. HCTL has 
shown to shift Ca2+ dependent ryanodine binding in cardiac muscle SR from a kd of 
73.5nM ± 1.8 to a kd of 43.2nM ± 2.3 at 100nM when the solution potential has been 
set to -210mV and pH 7.4 as shown in Figure 13.  
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Effects of 100nM HCTL on Ca2+ dependent ryanodine binding in 
Cardiac SR at pH 7.4 with and without a reducing solution potential
Free Ca2+ in solution (µM)
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Figure 13: Shift in Ca2+ dependent ryanodine binding in cardiac muscle due to 100nM 
HCTL. Control cardiac muscle SR at pH 7.4 and -210mV (●); +100nM 
HCTL at -210mV (▼); Control cardiac SR at pH 7.4 without redox 
potential set (■) +100nM HCTL without redox potential set (♦) 
 
At other concentrations of HCTL, 1nM, 10nM, 1µM the kd of the Ca
2+ dependence 
was within two standard deviations of the control as shown in Figure 14 and 
summarized in Table 3.  
 Control 10nM HCTL 100nM HCTL 1µM HCTL 
kd (nM) 73.5±1.8 69.6±1.3 42.1±2.4 70.8±8.6 
Table 3: Shift in Ca2+ dependent ryanodine binding kd as a function of HCTL 
concentrations 
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Effects of HCTL on Ca
2+
 dependent ryanodine binding in cardiac muscle SR at pH 7.4
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Figure 14: Shift in Ca2+ dependent ryanodine binding as a function of HCTL 
concentration in cardiac muscle SR. Control Cardiac SR at pH 7.4 (●) 
+10nM HCTL (▼) +100nM HCTL (■) +1µM HCTL (♦). All experiments 
aer carried out at -210mV solution redox potential.  
 
Skeletal muscle does not exhibit the biphasic effect of HCTL, however it does seem to 
have a effect on cooperativity, as the hill number generated from the fitof the 1µM 
addition of HCTL on Ca2+ dependent ryanodine binding is much less. Shifts in Ca2+
dependence is seen in Figure 15 and summarized in Table 4 with the largest shift 
occurring at 1µM HCTL.  
 Control 10nM HCTL 100nM HCTL 1µM HCTL 
kd (µM) 0.393±0.077 0.289±0.054 0.338±0.067 0.872±0.255 
Table 4: Shift in Ca2+ dependence kd in skeletal muscle SR due to various 
concentrations of HCTL 
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Effects of HCTL on Ca2+ dependent ryanodine binding in  
skeletal muscle SR at pH 7.4 
 
Figure 15: Shift in Ca2+ dependent ryanodine binding in skeletal muscle SR due to 
HCTL. Control skeletal SR at pH 7.4 (●); +10nM HCTL (▼) 
 +100nM HCTL (♦) +1µM HCTL (▲) 
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Chapter 4: Conclusions 
 
The effects of Ca2+ dependent activation is of major importance in the study of RyR 
since other channel modifiers cannot effect the channel in the absence of Ca2+, or they 
require Ca2+ for maximum activation. In this study of the high-affinity Ca2+ binding 
site, both an increase in pH and a more oxidative solution redox status increased 
binding as well as changed the amount of Ca2+ required for channel activation in both 
skeletal and cardiac muscle SR. These observation are in agreement with the 
previously reported conclusions that during muscle fatigue and a decrease in pH, 
higher concentrations of Ca2+ are required to stimulate contraction. 
 
Activation by an oxidative solution redox potential follow similar trends in both 
cardiac and skeletal muscle SR. At higher pH the ERyR values shift to the left, or a 
more reduced potential, while with the addition of an inhibitor, the ERyR value shifts to 
the right, or a more oxidizing potential. While the trends are similar the actual val es 
of the ERyR2 values are significantly more negative than the values that are found from 
skeletal muscle SR which is a possible explanation for why the RyR2 is much more 
easily oxidized than the RyR1.   
 
In skeletal muscle SR lower Ca2+ concentrations shift the redox potential to a more 
positive potential, as opposed to cardiac muscle SR where when the free Ca2+ 
concentrations drop below 30µM there ceases to be an activation even at very 
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oxidized redox solution potentials. Preliminary data shows that the cardiac receptor 
activity can be modulated by redox potential only when there is a free Ca2+ 
concentration between 30µM to 1mM. This is outside the range of physiological Ca2+ 
concentrations in the heart and raises questions about the role of redox potential as a 
modulator of RyR2. Although oxidative stress is a critical challenge to the SR’s ability 
to control Ca2+ homeostasis in the heart at this point it is not clear what role, if any, the 
redox potential plays in altering function of RyR2.  
 
Ranolazine desensitized the cardiac channel to activate by calcium which should lead 
to higher concentrations of Ca2+ being required to activate the channel under 
physiological conditions. During heart failure and arrhythmias it is known that the 
cellular Ca2+ concentration is elevated, ranolazine’s ability to desensitize the receptor 
to activation by Ca2+ should be beneficial towards maintaining calcium homeostasis 
under these conditions. It should prevent or decrease premature release of Ca2+ from 
the SR (arrhythmias). 
 
 Both Ranolazine and HCTL altered the Ca2+ dependence of ryanodine binding 
without effecting the maximum amount of binding. Surprisingly, the effect of HCTL 
was observed only in a reduced solution potential which leads us to speculate that the 
RyR’s response to HCTL is caused by an interaction with sulfhydryl groups on the 
protein being in a reduced state. The mechanism underlying this interaction is still 
under investigation. 
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